Understanding why skeletal muscles weaken in adult myotonic dystrophy type 1

Who could benefit from this research

What this research studies

Myotonic dystrophy type 1 (DM1) is a common muscular dystrophy caused by a toxic RNA from a CTG repeat in the DMPK gene. This project looks at how the altered RNA disrupts proteins that control RNA splicing in muscle, leading to abnormal muscle fibers and weakness. Scientists will explore the roles of MBNL and CELF1 proteins in adult skeletal muscle to pinpoint how their misregulation drives disease features. The work includes studying human muscle biology and may involve analyses of patient samples to connect molecular findings with muscle pathology. The ultimate goal is to identify targets that could inform future therapies to improve muscle function in DM1 patients.

Why it matters

Where this research is happening

• Baylor College of Medicine
  Houston, United States Active

Researchers

• Principal investigator: Cooper, Thomas a — Baylor College of Medicine
• Study coordinator: Cooper, Thomas a

Related research

Other NIH-funded projects on the same topics.

• New small molecule therapeutics to help myotonic dystrophy

  A new NIH-funded project tests specially designed small molecules to lower harmful RNA activity in myotonic dystrophy and related diseases, aiming to reduce disease-driving RNA effects.

  NIH research State University of New York at Albany · Albany, United States · NIH-11617693

• Mechanisms of muscle disease in myotonic dystrophy type 1

  This project looks at why skeletal muscles weaken and waste away in adults with myotonic dystrophy type 1 and aims to uncover the underlying molecular causes.

  NIH research Baylor College of Medicine · Houston, United States · NIH-11597907

• Extracellular vesicle biomarkers to monitor DM1 using urine and blood samples

  A study looking for easy, noninvasive biomarkers in urine and blood to track disease activity in people with myotonic dystrophy type 1.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-11494099

• Calcium Channel Blocker in DM1: Can amlodipine help myotonic dystrophy type 1

  This study tests whether the calcium‑channel blocker amlodipine can improve symptoms and survival in myotonic dystrophy type 1 (DM1).

  NIH research University of Rochester · Rochester, United States · NIH-11444061

• Preparing therapies for DM1 across ages, with a focus on children

  A broad, patient-focused effort to bring promising DM1 therapies to both children and adults by enriching trial readiness, biomarkers, and natural history data.

  NIH research Virginia Commonwealth University · Richmond, United States · NIH-11423652

• Biological factors that drive variability in myotonic dystrophy

  This grant explores why myotonic dystrophy can look very different from person to person by studying its genetic changes and how they affect muscle in adults.

  NIH research University of Florida · Gainesville, United States · NIH-11404431

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.